Advancing Health• Nov 24, 2025• 19:30

The Future of 340B: What Hospitals and Rural Communities Need to Know

From Advancing Health

Tina Fries-Decker

Executive Summary

The 340B Drug Pricing Program faces significant regulatory threats, primarily from a new HRSA rebate model pilot set to begin January 1st, which the American Hospital Association (AHA) argues will create severe financial and operational burdens for hospitals.
Hospitals, particularly rural and safety-net providers, rely heavily on 340B savings to fund essential but often unprofitable services, such as neonatal intensive care, behavioral health, and uncompensated care for vulnerable populations.
There is ongoing legislative scrutiny of the 340B program in Congress, with a focus on transparency and program growth, creating both risks of harmful reforms and opportunities for advocacy.
The AHA and hospital leaders are actively countering misinformation from program opponents by educating lawmakers and the public on how 340B savings are reinvested into patient care and community benefits.

12 quotes

Concerns Raised

The new HRSA rebate model will impose significant financial and operational burdens on hospitals.
Misinformation campaigns from drug manufacturers could lead to harmful legislative reforms.
Ongoing legal challenges threaten the viability of contract pharmacy arrangements.
Curtailment of the 340B program would force rural and safety-net hospitals to cut essential community services.

Opportunities Identified

Proactively educating lawmakers with specific data and patient stories can build strong support for the program.
Increasing transparency around the use of 340B savings can effectively counter negative narratives.
State-level legislation can serve as a powerful tool to protect hospital access to contract pharmacy partnerships.

Key Themes

Regulatory Overhaul and Financial Strain

The upcoming HRSA 340B rebate model pilot represents a fundamental shift from upfront drug discounts to a post-purchase rebate system. The AHA contends this forces hospitals to provide interest-free loans to drug manufacturers and will create significant new operational costs and cash flow challenges.

This change could destabilize the finances of safety-net hospitals that depend on the immediate savings from the 340B program to fund daily operations and essential community health services.

The Role of 340B in Sustaining Community Health

The discussion highlights how 340B savings are a critical lifeline for hospitals serving vulnerable communities. For example, Monument Health uses its $84 million in savings to offset over $123 million in uncompensated care and to directly fund services like neonatal care, behavioral health, and patient transportation that would otherwise be unsustainable.

Without 340B funding, many essential health services, especially in rural areas, would be at risk of being reduced or eliminated, directly impacting patient access to care.

Legislative Scrutiny and the Battle Over Narrative

Congress is showing increased interest in the 340B program's growth and is demanding more transparency in how savings are used. Opponents claim the program has grown too large, while the AHA argues this growth is a direct result of legislative expansions and, more importantly, soaring drug prices set by manufacturers.

The outcome of this narrative battle will shape future legislation. Effective advocacy and clear communication are crucial to prevent reforms that could gut the program's effectiveness.

Advocacy and Transparency as a Defense Strategy

Hospital leaders are urged to proactively engage with lawmakers and community stakeholders to demonstrate the program's value. By providing concrete examples and data on how 340B dollars are used—and putting a human face on the issue—hospitals can build a strong defense against legislative and regulatory threats.

In a climate of misinformation, transparently showcasing the direct link between 340B savings and patient services is the most effective tool for preserving the program's integrity and purpose.

State-Level Fights Over Contract Pharmacies

A key battleground for the 340B program is at the state level, where drug companies are legally challenging hospitals' ability to use contract pharmacies. In response, states like South Dakota are passing protective legislation to ensure hospitals can continue these partnerships, which are vital for patient access in many communities.

These state-level legal and legislative actions are critical for maintaining the operational infrastructure of the 340B program, as contract pharmacies are essential for dispensing discounted drugs to patients.

Get started free

Topics

340B Drug Pricing Program Healthcare Regulation Hospital Finance Pharmaceuticals Drug Pricing American Hospital Association (AHA)HRSA Rebate Model Uncompensated Care Rural Healthcare Community Benefit Healthcare Advocacy Contract Pharmacy Legislative Oversight Safety-Net Hospitals

Processed Apr 20, 2026 yt-dlp + mlx-whisper + Gemini